Product Description
He aha ka Tirzepatide?
He lāʻau lapaʻau hou ʻo Tirzepatide i ʻae ʻia e FDA no ka mālama ʻana i ka maʻi diabetes mellitus type 2. Ma muli o kāna mau waiwai pohō kaumaha, kūʻai i ka tirzepatide e hoʻohana ʻia ma waho-label no ka mālama ʻana i ka momona.
Hana ia ma ke ʻano he ʻelua GLP-1 agonist a me GIP agonist e hoʻonui i nā pono like i ʻike ʻia me nā lāʻau lapaʻau GLP-1 e like me semaglutide.Ke hoʻokō ʻia nei ia ma ke ʻano he lāʻau lapaʻau maʻi diabetes laina lua, e like me nā lāʻau lapaʻau GLP-1, a hāʻawi ʻia ma ke ʻano he subcutaneous injectable i hoʻokahi pule.
Pehea e hana ai ʻo Tirzepatide?
ʻO Tirzepatide kahi peptide synthetic; a me ka agonist receptor agonist like me ka glucagon-like peptide 1 (GLP-1) he 39 amino acids a he analike ia o ka polypeptide inhibitory o ka ʻōpū. ke alakaʻi nei i ka emi ʻana o ka hyperglycemia. Eia kekahi, hoʻonui pū ʻo Tirzepatide i nā pae o adiponectin. ʻO kona hiki ʻelua agonism hiki ke alakaʻi i kahi hōʻemi nui o ka hyperglycemia ma mua o nā mea agonist GLP-1 wale nō a hoʻohaʻahaʻa i ka makemake o ka mea hoʻohana.
Nā Pōmaikaʻi Tirzepatide
ʻO Tirzepatide kahi mea hoʻokipa glucose-dependent insulinotropic polypeptide (GIP) a me glucagon-like peptide-1 (GLP-1) receptor agonist, ʻo ia ka FDA-apono ʻia no ka mālama ʻana i ka maʻi diabetes mellitus type 2. He mea nui e hoʻomaopopo ʻaʻole ʻae ʻia ka tirzepatide ka mālama ʻana i ka maʻi diabetes type-1 a ʻaʻole i aʻo ʻia i nā poʻe maʻi me ka pancreatitis. ʻO Tirzepatide he GIP receptor a me GLP-1 receptor agonist, e alakaʻi ana i ka hoʻomaikaʻi maikaʻi ʻana i ka mana glycemic i nā maʻi maʻi type 2 a me ka hoʻemi nui o ke kaumaha.
Nā hopena o Tirzepatide
ʻO ka poʻe maʻi me ka momona a me ka maʻi diabetes type 2 (T2D) a i ʻole me ke kaumaha nui a me ka T2D ua nalowale kahi 34.4 paona (15.7%) o ke kaumaha o ke kino me 10 mg a me 15 mg o tirzepatide (Mounjaro; Eli Lilly a me Company), e like me nā ʻike mai ka SURMOUNT -2 hoʻāʻo pae honua 3. ʻOiai, ʻo ka tirzepatide ma 10 mg i hoʻemi i ke kaumaha o ke kino e 5% a ʻoi aʻe paha i 79.2% o nā mea maʻi a hoʻemi ʻia ke kaumaha o ke kino e 12.8%, ʻoiai ʻo ka 15 mg i hoʻemi i ke kaumaha ma 82.7% o nā mea maʻi a emi iho ka awelika. ke kaumaha o ke kino e 14.7%.
Hoʻohana ʻia ʻo Tirzepatide no ka pohō kaumaha
ʻO Tirzepatide, he injection hoʻokahi pule i kēlā me kēia pule e hoʻemi i ke kō koko. Mai ka makahiki 2022 ua hōʻike ʻo ia i nā hopena hoʻemi koʻikoʻi, a aia ma ke ala wikiwiki no kāna loiloi no ka mālama ʻana i ka momona. ʻoi aku ma mua o 20% o ko lākou kaumaha kino mua.
ʻO Tirzepatide a me BPC 157 kōkua i ka pohō kaumaha ma ka hoʻemi ʻana i ka ʻai ʻana a me ka hoʻolohi ʻana i ka holo wikiwiki ʻana o ka meaʻai ma kāu ʻāpana digestive. Hiki ke kōkua kēia iā ʻoe e ʻoi aku ka lōʻihi o ka piha a hoʻemi i ka nui o ka meaʻai āu e ʻai ai.
Pehea ia hana:
●E ho'ēmi i ka nui o ka meaʻai i ʻai ʻia.
● Hoʻopau i ke akepaʻa mai ka hana ʻana a me ka hoʻokuʻu ʻana i ke kō.
●Hoʻolohi i ka haʻalele ʻana o ka ʻai i ka ʻōpū.
●Hoʻokuʻu ke kino i ka insulin ke kiʻekiʻe ke kō koko.
●Hoʻopau ke kino i ke kō mai ke koko.
He aha ka ʻokoʻa ma waena o Tirzepatide a me Semaglutide?
Hana ʻo Tirzepatide i nā mea loaʻa ʻelua GIP a me GLP-1, ʻoiai ʻo Semaglutide e hana wale ana ma nā mea loaʻa GLP-1. ʻO nā lāʻau ʻelua he mau lāʻau lapaʻau maikaʻi loa. -like peptide-1) receptor agonist. Aia nā mea ʻelua i ka papa o nā lāʻau i ʻike ʻia he incretin mimetics akā loaʻa kekahi mau ʻokoʻa.
ʻO ka hoʻololi ʻana i ke ʻano o ka nohona a me ka hoʻopaʻa ʻana i ka calorie e alakaʻi i nā hopena maikaʻi aʻe. ʻO nā pōmaikaʻi o ka pohō kaumaha ka hoʻomaikaʻi ʻana i nā comorbidities o ka momona e like me ka maʻi diabetes, ke koko kiʻekiʻe, nā lipids koko ʻole a me ka maʻi puʻuwai hiki ke ʻike ʻia me ka liʻiliʻi e like me ka 5% pohō kaumaha.
Nā hopena ʻaoʻao ʻo Tirzepatide
ʻO nā hopena ʻaoʻao maʻamau o Tirzepatide, ʻo ia ka nausea, ka ʻōpū, ka emi ʻana o ka ʻai, ka luaʻi ʻana, ka constipation, ka ʻeha ʻana, a me ka ʻeha o ka ʻōpū (ʻōpū). ʻike.
Ma hea e kūʻai ai iā Tirzepatide?
ʻO AASraw kahi maikaʻi loa e kūʻai aku ai iā Tirzepatide wholesale.ʻO kā mākou huahana a pau e hele mai me kahi palapala hōʻoia kūʻokoʻa kūʻokoʻa i hāʻawi ʻia e nā ʻaoʻao ʻekolu no ka ʻike ʻana, ka maʻemaʻe, a me ka noʻonoʻo.
ʻO AASraw ka mea hoʻolako Tirzepatide a me ka mea hana Tirzepatide nona ka hale kūʻokoʻa kūʻokoʻa a me ka hale hana nui e like me ke kākoʻo, e hana ʻia nā hana āpau ma lalo o ke kānāwai CGMP a me ka ʻōnaehana mālama maikaʻi trackable. e kūʻai iā Tirzepatide ma ka pūnaewele, e kipa aku i kā mākou pūnaewele (aasraw.com).
Hōʻike hoʻāʻo ʻo Tirzepatide-HNMR
He aha ka HNMR a He aha ka HNMR spectrum e haʻi aku iā ʻoe? ʻO H Nuclear Magnetic Resonance (NMR) spectroscopy kahi ʻenehana kemika analytical i hoʻohana ʻia i ka hoʻokele maikaʻi a me ka noiʻi no ka hoʻoholo ʻana i ka ʻike a me ka maʻemaʻe o kahi laʻana a me kona ʻano molekala. No ka laʻana, hiki i ka NMR ke hoʻokaʻawale i nā hui pū ʻia i ʻike ʻia. No nā pūhui i ʻike ʻole ʻia, hiki ke hoʻohana ʻia ka NMR e hoʻohālikelike i nā hale waihona puke spectral a i ʻole e kuhi pololei i ke ʻano kumu. Ke ʻike ʻia ke ʻano kumu, hiki ke hoʻohana ʻia ka NMR no ka hoʻoholo ʻana i ka conformation molecular i ka hopena a me ke aʻo ʻana i nā waiwai kino ma ka pae molekala e like me ka hoʻololi conformational, nā hoʻololi ʻana, ka solubility, a me ka diffusion.
Pehea e kūʻai ai iā Tirzepatide mai AASraw?
❶E hoʻokaʻaʻike mai iā mākou ma kā mākou ʻōnaehana nīnau leka uila, a i ʻole e waiho i kāu helu whatsapp iā mākou, e hoʻopili aku kā mākou mea kūʻai aku (CSR) me ʻoe i 12 mau hola.
❷E hāʻawi mai iā mākou i kāu helu a me kāu helu wahi i nīnau ʻia.
❸Na kā mākou CSR e hāʻawi iā ʻoe i ka ʻōlelo, ka manawa uku, ka helu ʻimi, nā ala hoʻouna a me ka lā i manaʻo ʻia (ETA).
❹E uku ʻia a hoʻouna ʻia nā waiwai i loko o 12 mau hola.
❺ Loaʻa nā waiwai a hāʻawi i nā manaʻo.
Mea kākau o kēia ʻatikala:
Kauka Monique Ua puka 'o Hong mai ke Kula Nui o UK Imperial College London Faculty of Medicine
Mea kākau moʻolelo puke moʻolelo ʻepekema:
1. Qi Liu
Keʻena o Cardiology, Renmin Hospital o Wuhan University, Wuhan 430060, Hubei, PR Kina
2. Sidar Copur
Keʻena Lapaʻau, Koc University School of Medicine, Istanbul 34010, Turkey
3. Rouchan Ali
Keʻena ʻOihana Kimia Lapaʻau a me ka ʻIkepili, ISF College of Pharmacy, Moga 142001, Punjab, India
4. V. Thieu
ʻO Eli Lilly, Kauka Lapaʻau, Indianapolis, USA
ʻAʻole ʻae kēia kauka/ ʻepekema i ke kūʻai, kūʻai ʻana, a hoʻohana paha i kēia huahana no kekahi kumu. ʻAʻohe pili a pili ʻole ʻo Aasraw, i hōʻike ʻia a i ʻole, me kēia kauka. ʻO ke kumu o ka haʻi ʻana i kēia kauka, ʻo ia ka hoʻomaikaʻi, hoʻomaikaʻi a hoʻomaikaʻi i ka hana noiʻi a me ka hoʻomohala piha i hana ʻia e nā ʻepekema e hana nei i kēia mea.
E hoʻomaopopo '
[1] Lilly: Hōʻike ʻia nā hopena ʻo Tirzepatide Phase 3 kiʻekiʻe A1C a me nā hōʻemi ʻana o ke kino ma ke ʻano maʻi diabetes type 2. Business Insider.RTTNews.
[2] Ua hoʻemi nui ʻo Tirzepatide i ka A1C a me ke kaumaha o ke kino i ka poʻe me ka maʻi maʻi type 2 i ʻelua mau hoʻāʻo ʻana 3 mai ka papahana SURPASS a Lilly" (Press release). - ma o PR Newswire.
[3] Kelaher,Colin (28 ʻApelila 2022).
[4] Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, et al. .doi:2020/jci.insight.1.PMC 5.PMID 17.
[5] Frederick MO, Boyse RA, Braden TM, Calvin JR, Campbell BM, Changi SM, et al. (2021). .25 (7):1628–1636.
[6] ʻO Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. (ʻAukake 2021). (2):385–6.doi:503/NEJMoa515.
E kiʻi i kahi hōʻaiʻē nui
